Front Immunol, 2024, 15:1493877

Biomarkers of success of anti-PD-(L)1 immunotherapy for non-small cell lung cancer derived from RNA- and whole-exome sequencing: results of a prospective observational study on a cohort of 85 patients

Immune checkpoint inhibitors (ICIs) treatment have shown high efficacy for about 15 cancer types. However, this therapy is only effective in 20-30% of cancer patients. Thus, the precise biomarkers of ICI response are an urgent need.

Poddubskaya E, Suntsova M, Lyadova M, Luppov D, Guryanova A, Lyadov V, Garazha A, Sorokin M, Semenova A, Shatalov V, Biakhova M, Simonov A, Moisseev A, Buzdin A

Department of Genomics and Postgenomic Technologies, Group for Genomic Regulation of Cell Signaling Systems

: 10.3389/fimmu.2024.1493877
Scopus: 2-s2.0-85213044060
: 39723204
IBCH: 11702
Ссылка на статью в журнале: https://www.frontiersin.org/articles/10.3389/fimmu.2024.1493877/full
Кол-во цитирований на 04.2026: 5
Данные статьи проверены модераторами 2025-01-15

Список научных проектов, где отмечена публикация

  1. FSMG-2021–0006. . Сommercial.
  2. 075-03-2024-117. . Сommercial.
  3. 22-14-00074. . Сommercial.